Open Access Open Access  Restricted Access Subscription or Fee Access

Burkitt Lymphoma: A Potentially Curable Childhood Tumour: Experience in Ile-Ife, Nigeria (1986-2014)

M. A. Durosinmi

Abstract


Background: Burkitt lymphoma (BL) is the commonest tumour among Nigerian children. It is reported to be highly responsive to readily available cytotoxic drugs; yet, the outcome of therapy remains abysmal.

Objectives: To review the epidemiology of BL in terms of risk factors, age incidence, regional distribution, disease sub-types, examine the available treatment regimens locally and internationally and report on the outcome of treatment in Nigeria under different conditions.

Methods: A comprehensive literature review on the epidemiology of BL was undertaken and results of publications and clinical trials of BL were evaluated. 

Results: Three major sub-types of Burkitt lymphoma are recognised in the world literature; the classic endemic BL (eBL) in sub-Saharan Africa, EBV-independent sporadic BL (sBL) found in population outside the endemic areas and the HIV-related BL (HIV-BL), which is found in regions with high incidence of HIV infection. All the sub-types have common cytogenetic abnormalities: t (8, 14), t (8, 22), and t (2, 8). The COM regimen incorporating cyclophosphamide, oncovin and methotrexate (with the intrathecal cytarabine and methotrexate), was found to be very effective for eBL. Treatment outcome was dismal for the self-financed patients treated with COM regimen between 1986 and 2000 (Group A) compared to the internationally sponsored patients treated between 2000 and 2014 (Group B). While 16.8% of Group A patients had no chemotherapy, 9.8% were lost to toxic deaths and 88% defaulted; most of the patients in group B had full chemotherapy; the Event-Free Survival (EFS) rates at 12 and 24 months were 58.3% and 53.4%, respectively.

Conclusions: COM regimen with intrathecal cytarabine and methotrexate is very effective for eBL. 


Keywords


Burkitt lymphoma; Cyclophosphamide; Intrathecal; Methotrexate; Oncovin

Full Text:

PDF

References


Burkitt D. A sarcoma involving the jaws in African children. Br J Surg 1958; 46(197): 218–223.

Ian Magrath. Epidemiology: clues to the pathogenesis of Burkitt lymphoma. International Network for Cancer Treatment and Research, Brussels, Belgium and the National Cancer Institute, Bethesda, MD, USA. Br J Haematol 2012; 156: 744–756.

Wiggill TM1, Mantina H, Willem P, Perner Y, Stevens WS. Changing pattern of lymphoma subgroups at a tertiary academic complex in a high-prevalence HIV setting: a South African perspective. J Acquir Immune Defic Syndr 2011; 56(5): 460-466.

Henle G, Henle W. Immunofluorescence in cells derived from Burkitt’s lymphoma. J Bacteriol 1966; 91: 1248-1256.

Beral V1, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet 1991; 337(8745): 805-809.

Parkin DM1, Garcia-Giannoli H, Raphael M, Martin A, Katangole-Mbidde E, Wabinga H, Ziegler J. Non-Hodgkin lymphoma in Uganda: a case-control study. AIDS 2000; 14(18): 2929-2936.

Bornkamm GW. Epstein-Barr virus and the pathogenesis of Burkitt's lymphoma: more questions than answers. Int J Cancer 2009; 124(8): 1745-1755.

Habeshaw G, Yao QY, Bell AI, Morton D, Rickinson AB. Epstein-Barr Virus Nuclear Antigen 1 Sequences in Endemic and Sporadic Burkitt’s Lymphoma Reflect Virus Strains Prevalent in Different Geographic Areas. J Virol 1999; 73(2): 965-975.

Dalla-Favera, R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human cmyc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America. 1982; 79: 7824–7827.

De Souza MT, Hassan R, Liehr T, Marques-Salles TJ, Boulhosa AM, Abdelhay E, Ribeiro RC, Silva ML. Conventional and molecular cytogenetic characterization of Burkitt lymphoma with bone marrow involvement in Brazilian children and adolescents. Pediatr Blood Cancer 2014; 61(8): 1422-1426.

Wright DH. What is Burkitt’s lymphoma and when is it endemic? Blood 1999; 93(2): 758.

Lenze D, Leoncini L, Hummel M, Volinia S, Liu CG, Amato T, et al. The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Leukemia 2011; 25: 1869–1876.

Salawu L, Fatusi OA, Kemi-Rotimi F, Adeodu OO, Durosinmi MA. Familial Burkitt's lymphoma in Nigerians. Ann Trop Paediatr 1997; 17(4): 375-379.

Burkitt D and Wright D. Geographical and Tribal distribution of African Lymphoma in Uganda. British Med J 1966; 1(5487): 569–573.

Ngoma T, Adde M, Durosinmi M, Githang’a J, Aken’Ova Y, Kaijage J, et al. Treatment of Burkitt lymphoma in equatorial Africa using a simple three-drug combination followed by a salvage regimen for patients with persistent or recurrent disease. Br J Haematol 2012; 158(6): 749–762. doi:10.1111/j.1365-2141.2012.09236.x.

Adelusola KA, Odesanmi WO, Adejuyigbe O, Rufai OA, Durosinmi MA, Akinola NO. Malignant solid tumours in Nigerian children. Cent Afr J Med 1995; 41(10):322-326.

Brown BJ. A review of the literature on childhood Burkitt lymphoma in Nigeria. Niger J Paed 2016; 43 (1): 1 –7 DOI:http://dx.doi.org/10.4314/njp.v43i1.1.

Kagu MB, Durosinmi MA, Adeodu OO, Akinola NO, Adediran IA, Salawu L. Determinants of survival in Nigerians with Burkitt's lymphoma. Afr J Med Med Sci 2004; 33(3): 195-200.

Magrath IT. African Burkitt’s lymphoma. Am J Pediatr Hematol Oncol 1991; 13(2): 222-246.

Divine M, Casassus P, Koscienly S, Bosq J, Sebban C, Le Maignan C, et al. [On behalf of GELA and GOELAMS]. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol 2005; 16: 1928–1935.

Lawal OO, Ojo OS, Durosinmi MA. Burkitt's lymphoma in a 45-year-old Nigerian woman. Trop Geogr Med. 1990; 42(3): 294-297.

Linch DC. Burkitt lymphoma in adults. Br J Haematol 2012; 156: 693–703.

Adeoye AO, Durosinmi MA, Adeodu OO, Kagu MB, Olateju SO, Olowu WA et al. Ocular manifestations of Burkitt's lymphoma: experience in Ile-Ife south western Nigeria. West Afr J Med. 2007; 26 (1): 48-52.

Judith A. Ferry. Burkitt’s Lymphoma: Clinicopathologic Features and Differential Diagnosis. The Oncologist 2006; 11:375–383.

Ajibade AD. Assessment of cytologic diagnosis of childhood non-Hodgkin lymphoma using immunocytochemistry in OAUTHC, Ile-Ife. A dissertation submitted to the National Postgraduate Medical College of Nigeria in partial fulfilment of the requirements for the award of Fellowship in Pathology (FMCPath). October 2015.

Ziegler JL, Magrath IT, Olweny CL. Cure of Burkitt's lymphoma. Ten-year follow-up of 157 Ugandan patients. Lancet 1979; 2(8149): 936-938.

Olweny CLM, Toya T, Katongole-Mbidde E, et al. Long-term experience with Burkitt's lymphoma in Uganda. Int J Cancer 1980; 26: 261-266.

Ziegler JL, Morrow RH, Fass L, et al. Treatment of Burkitt’s tumor with cyclophosphamide. Cancer 1969; 26: 474-484.

Williams CK, Folami AO, Seriki O. Patterns of treatment failure in Burkitt's lymphoma. Eur J Cancer Clin Oncol 1983; 19: 741-746.

Fasola FA, Shokunbi WA, Falade AG. Factors determining the outcome of management of patients with Burkitt's lymphoma at the University College Hospital, Ibadan, Nigeria: an eleven-year review. Niger Postgrad Med J 2002; 9: 108-112.

Oguonu T, Emodi I, Kaine W. Epidemiology of Burkitt's lymphoma in Enugu, Nigeria. Ann Trop Paediatr 2002; 22: 369-374.

Williams CKO. High-Dose Cytosine Arabinoside Chemotherapy of Burkitt Lymphoma: Advocating Sustainable Strategies for Capacity Building in Systemic Cancer Care in Nigeria. Chemo Open Access 2015; 4: 4 (http://dx.doi.org/10.4172/2167-7700.1000167).

Diebold J. Burkitt lymphoma. In: Jaffe E, Harris N, Stein H, et al. (Eds). Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Washington, DC: IARC Press. 2001:181–184.

Durosinmi MA and Adediran I. Management of cancer under structural adjustment programme (SAP): Experience in Ile-Ife Nigeria Niger Med J 1993; 25(3): 92-96.

Magrath IT, Haddy TB, Adde MA. Treatment of patients with high grade non-Hodgkin's lymphomas and central nervous system involvement: is radiation an essential component of therapy? Leuk Lymphoma 1996; 21(1-2): 99-105.

Olowu WA, Elusiyan JBE, Badejo SA, Adenowo OA. Acute Renal Failure in African children with Burkitt’s Lymphoma: A comparison of two treatment regimens. Pediatr Blood Cancer 2006; 46: 446–453.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 Annals of Health Research



A publication of the Medical and Dental Consultants Association of Nigeria, Olabisi Onabanjo University Teaching Hospital, (OOUTH) Sagamu Branch, Nigeria